Interactions between 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan) and alpha-adrenergic blocking drugs.
D000200:Action Potentials; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002572:Cervical Plexus / Q000187:drug effects; D004285:Dogs; D006321:Heart / Q000294:innervation; D007093:Imidazoles / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D008526:Medulla Oblongata; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D013153:Splanchnic Nerves / Q000187:drug effects*; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013565:Sympatholytics / Q000494:pharmacology*; D014043:Tolazoline / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D007093:Imidazoles; D013565:Sympatholytics; D010643:Phenoxybenzamine; D014043:Tolazoline; D010646:Phentolamine